{"id":"https://openalex.org/W4281295076","doi":"https://doi.org/10.2217/fon-2022-0276","title":"Momelotinib for the treatment of myelofibrosis with anemia","display_name":"Momelotinib for the treatment of myelofibrosis with anemia","publication_year":2022,"publication_date":"2022-05-23","ids":{"openalex":"https://openalex.org/W4281295076","doi":"https://doi.org/10.2217/fon-2022-0276","pmid":"https://pubmed.ncbi.nlm.nih.gov/35603634"},"language":"en","primary_location":{"id":"doi:10.2217/fon-2022-0276","doi":"https://doi.org/10.2217/fon-2022-0276","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2022-0276","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.2217/fon-2022-0276","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085185312","display_name":"Douglas A. Tremblay","orcid":"https://orcid.org/0000-0002-4719-7192","observed_orcids":["https://orcid.org/0000-0002-4719-7192","https://orcid.org/0000-0003-2584-6953"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Tremblay","raw_affiliation_strings":["Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,\rNew York, NY,\rUSA"],"raw_orcid":"https://orcid.org/0000-0002-4719-7192","affiliations":[{"raw_affiliation_string":"Tisch Cancer Institute,Icahn School of Medicine at Mount Sinai,\rNew York, NY,\rUSA","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4390039360","display_name":"Mays Cancer Center at UT Health San Antonio","ror":"https://ror.org/04aysmc18","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165951966","https://openalex.org/I4390039360","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben Mesa","raw_affiliation_strings":["UT Health San Antonio Cancer Center,\rSan Antonio, TX,\rUSA"],"raw_orcid":"https://orcid.org/0000-0001-5880-7972","affiliations":[{"raw_affiliation_string":"UT Health San Antonio Cancer Center,\rSan Antonio, TX,\rUSA","institution_ids":["https://openalex.org/I4390039360"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6182,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.53321879,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"18","issue":"20","first_page":"2559","last_page":"2571"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13374","display_name":"Hematological disorders and diagnostics","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/momelotinib","display_name":"momelotinib","score":1.0},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9610000252723694},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.6990000009536743},{"id":"https://openalex.org/keywords/jak1-2-inhibitor","display_name":"JAK1/2 inhibitor","score":0.9229999780654907},{"id":"https://openalex.org/keywords/hepcidin","display_name":"hepcidin","score":0.9890000224113464},{"id":"https://openalex.org/keywords/iron-availability","display_name":"iron availability","score":0.8939999938011169},{"id":"https://openalex.org/keywords/erythropoiesis","display_name":"erythropoiesis","score":0.9800000190734863},{"id":"https://openalex.org/keywords/transfusion-burden","display_name":"transfusion burden","score":0.8069999814033508},{"id":"https://openalex.org/keywords/spleen-size","display_name":"spleen size","score":0.8360000252723694},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.8579999804496765},{"id":"https://openalex.org/keywords/hemoglobin-improvement","display_name":"hemoglobin improvement","score":0.6299999952316284}],"concepts":[{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.9529777765274048},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8855034112930298},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.7927586436271667},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.6424449682235718},{"id":"https://openalex.org/C2779703530","wikidata":"https://www.wikidata.org/wiki/Q837174","display_name":"Erythropoiesis","level":3,"score":0.5019409656524658},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4855315685272217},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.466397225856781},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.46256858110427856},{"id":"https://openalex.org/C2778917026","wikidata":"https://www.wikidata.org/wiki/Q43041","display_name":"Hemoglobin","level":2,"score":0.4620117247104645},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3392980694770813},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3310295641422272}],"mesh":[{"descriptor_ui":"D000075242","descriptor_name":"Janus Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000740","descriptor_name":"Anemia","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D053614","descriptor_name":"Janus Kinase 2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.2217/fon-2022-0276","doi":"https://doi.org/10.2217/fon-2022-0276","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2022-0276","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},{"id":"pmid:35603634","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35603634","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future oncology (London, England)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.2217/fon-2022-0276","doi":"https://doi.org/10.2217/fon-2022-0276","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2022-0276","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":61,"referenced_works":["https://openalex.org/W1534089060","https://openalex.org/W1970111821","https://openalex.org/W1980042430","https://openalex.org/W1980724348","https://openalex.org/W1997867585","https://openalex.org/W2010293026","https://openalex.org/W2010298229","https://openalex.org/W2017468796","https://openalex.org/W2025063713","https://openalex.org/W2025109100","https://openalex.org/W2037827850","https://openalex.org/W2049912996","https://openalex.org/W2061377922","https://openalex.org/W2066937360","https://openalex.org/W2069327111","https://openalex.org/W2071990094","https://openalex.org/W2072575368","https://openalex.org/W2073193141","https://openalex.org/W2089753725","https://openalex.org/W2107373252","https://openalex.org/W2113062534","https://openalex.org/W2115351357","https://openalex.org/W2121743767","https://openalex.org/W2127559749","https://openalex.org/W2149055075","https://openalex.org/W2411784329","https://openalex.org/W2511586498","https://openalex.org/W2521045502","https://openalex.org/W2534149640","https://openalex.org/W2586215211","https://openalex.org/W2613940568","https://openalex.org/W2622547803","https://openalex.org/W2731573311","https://openalex.org/W2754551124","https://openalex.org/W2764282137","https://openalex.org/W2768672347","https://openalex.org/W2768722269","https://openalex.org/W2771403719","https://openalex.org/W2776878294","https://openalex.org/W2778275419","https://openalex.org/W2791240656","https://openalex.org/W2907774005","https://openalex.org/W2991379201","https://openalex.org/W2996087467","https://openalex.org/W3008023739","https://openalex.org/W3009670005","https://openalex.org/W3010774459","https://openalex.org/W3085980128","https://openalex.org/W3096573094","https://openalex.org/W3097677520","https://openalex.org/W3111766821","https://openalex.org/W3112384611","https://openalex.org/W3119071615","https://openalex.org/W3161919645","https://openalex.org/W3165929791","https://openalex.org/W3200542521","https://openalex.org/W4200050697","https://openalex.org/W4206302502","https://openalex.org/W4210532855","https://openalex.org/W4210900706","https://openalex.org/W4213142561"],"related_works":["https://openalex.org/W4401927200","https://openalex.org/W4409560287","https://openalex.org/W4206302502","https://openalex.org/W4410153581","https://openalex.org/W4400014634","https://openalex.org/W6958457794","https://openalex.org/W4394853841","https://openalex.org/W4401909908","https://openalex.org/W2900220084","https://openalex.org/W4404994507"],"abstract_inverted_index":{"Myelofibrosis":[0],"is":[1,17,40],"a":[2,41,67],"myeloproliferative":[3],"neoplasm":[4],"characterized":[5],"by":[6],"splenomegaly,":[7],"debilitating":[8],"constitutional":[9],"symptoms":[10],"and":[11,19,27,54,73,89,101],"bone":[12],"marrow":[13],"failure.":[14],"Disease-related":[15],"anemia":[16],"common":[18],"associated":[20],"with":[21,80],"an":[22],"inferior":[23],"quality":[24],"of":[25,51,57,104,111],"life":[26],"survival.":[28],"Unfortunately,":[29],"few":[30],"therapies":[31],"exist":[32],"to":[33,49,70],"improve":[34,71],"hemoglobin":[35,72],"in":[36,77,86,106],"myelofibrosis":[37,78],"patients.":[38],"Momelotinib":[39],"JAK1/JAK2":[42],"inhibitor":[43],"that":[44],"also":[45],"antagonizes":[46],"ACVR1,":[47],"leading":[48],"downregulation":[50],"hepcidin":[52],"expression":[53],"increased":[55],"availability":[56],"iron":[58],"for":[59],"erythropoiesis.":[60],"In":[61],"clinical":[62,98],"testing,":[63],"momelotinib":[64,105],"has":[65],"demonstrated":[66],"unique":[68],"ability":[69],"reduce":[74],"transfusion":[75],"burden":[76],"patients":[79],"baseline":[81],"anemia,":[82],"while":[83],"producing":[84],"reductions":[85],"spleen":[87],"size":[88],"symptom":[90],"burden.":[91],"This":[92],"review":[93],"explores":[94],"the":[95,107],"preclinical":[96],"rationale,":[97],"trial":[99],"data":[100],"future":[102],"role":[103],"evolving":[108],"therapeutic":[109],"landscape":[110],"myelofibrosis.":[112]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-24T00:00:00"}